Transcatheter tricuspid valve-in-valve replacement in a patient with Ebstein’s anomaly: a case report and brief review
General Medicine, 2024, 26(5), 11-15.
G. Stoitsev1, V. Geguskov1,2
1 Department of Cardiac Surgery, UMHAT “Sv. Anna” ‒ Sofia
2 Medical University ‒ Pleven
Abstract. Ebstein’s anomaly is a rare congenital heart malformation of the tricuspid valve and right ventricle with a wide range of clinical and morphological manifestations. The disease accounts for less than 1% of all congenital heart defects. The appearance of clinical symptoms leading to heart failure determines the need for operative correction of the malformation. The majority of surgical procedures for Ebstein’s anomaly consist of valve replacement and a biological prosthesis is the device of choice. Implantation of a biological prosthesis is associated with a significantly higher risk of reoperation caused by degeneration and valve dysfunction, especially in young patients. This article aims to describe the outcome of transcatheter tricuspid valve-in-valve (TVIV) implantation of a MyVal prosthesis (Meril Life Sciences Pvt. Ltd) for the treatment of a patient with Ebstein’s anomaly after previous biological valve implantation.
Key words: transcatheter valve replacement, Ebstain’s anomaly, tricuspid valve
Address for correspondence: Assoc Prof. Vasil Geguskov, MD, PhD, е-mail: vassilgegouskov@arcor.de